CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor.

Induction of a polycyclic aromatic hydrocarbon-metabolizing cytochrome P450 isoform CYP1A1 is regulated by aromatic hydrocarbon receptor (AHR). High inducibility of CYP1A1, possibly due to genetic polymorphisms, has been considered to be a risk factor for lung cancer in tobacco smokers. The relationship between low or high pulmonary expression of CYP1A1 and polymorphic genotypes of CYP1A1 and AHR was investigated in 73 active smokers. CYP1A1 expression was determined in surgical lung samples by measuring ethoxyresorufin O-deethylase (EROD) activity and by immunostaining for CYP1A1 protein. The most common allelic variants of CYP1A1 and AHR in Finns, i.e. the MspI variant (CYP1A1*2A), I462V variant (CYP1A1*2B), and -459C to T variant of CYP1A1 and the R554K variant (AHR*2) of AHR were studied using polymerase chain reaction based methods. EROD activity correlated positively with the daily cigarette consumption (r = 0.45). There was additional variation in EROD activity independent of the amount of smoking e.g. among those who smoked one pack per day until the day of operation, EROD activity ranged from 4-142 (median 48) pmol/min/mg. The frequencies of the MspI, 462V, and -459T variant alleles of CYP1A1 and 554K variant allele of AHR were 0.158, 0.055, 0.055 and 0.075, respectively. No differences were observed in the frequencies of polymorphic genotypes between the smokers with low and those with high expression, when the relationship was studied using a regression analysis adjusted for cigarette consumption. Our results thus indicate that the interindividual variation of CYP1A1 levels in smokers' lung tissue is not attributable to genetic polymorphisms of CYP1A1 or AHR tested in this study.

[1]  H. Bartsch,et al.  Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. , 1992, Environmental health perspectives.

[2]  S. Anttila,et al.  Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  H. Bartsch,et al.  Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients , 1991, International journal of cancer.

[4]  R A Gibbs,et al.  Detection of single DNA base differences by competitive oligonucleotide priming. , 1989, Nucleic acids research.

[5]  A. Brøgger,et al.  Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. , 1991, Pharmacogenetics.

[6]  K. Nakachi,et al.  The CYP1A1 gene and cancer susceptibility. , 1993, Critical reviews in oncology/hematology.

[7]  C. Kiyohara,et al.  Polymorphisms of human Ah receptor gene are not involved in lung cancer. , 1995, Pharmacogenetics.

[8]  K. Nakachi,et al.  Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P45 0IA1 gene , 1990, FEBS letters.

[9]  Cell-specific regulation of human CYP1A1 and CYP1B1 genes. , 1997, Cancer research.

[10]  J. Gustafsson,et al.  Aryl hydrocarbon receptor-mediated signal transduction. , 1997, Critical reviews in toxicology.

[11]  J. Brockmöller,et al.  A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. , 1996, Cancer research.

[12]  H. Bartsch,et al.  An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. , 1992, Cancer research.

[13]  J. Ward,et al.  Immunohistochemical determination of inducibility phenotype with a monoclonal antibody to a methylcholanthrene-inducible isozyme of cytochrome P-450. , 1987, Cancer research.

[14]  T. Mitsudomi,et al.  Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese , 1995, International archives of occupational and environmental health.

[15]  F. Guengerich,et al.  Monoclonal antibodies that inhibit enzyme activity of 3-methylcholanthrene-induced cytochrome P-450. , 1982, Cancer research.

[16]  G. Clark,et al.  Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. , 1994, Pharmacogenetics.

[17]  D. Christiani,et al.  Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  K. Tanaka,et al.  The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. , 1998, Pharmacogenetics.

[19]  E. Taioli,et al.  Functional significance of different human CYP1A1 genotypes. , 1994, Carcinogenesis.

[20]  A. Rannug,et al.  Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. , 1994, Carcinogenesis.

[21]  S. Anttila,et al.  Localization of CYP1A1 mRNA in human lung by in situ hybridization: Comparison with immunohistochemical findings , 1998, International journal of cancer.

[22]  R. Mayer,et al.  Direct fluorometric methods for measuring mixed function oxidase activity. , 1978, Methods in enzymology.

[23]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[24]  K. Nakachi,et al.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. , 1991, Journal of biochemistry.

[25]  J. Smart,et al.  Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. , 2000, Pharmacogenetics.

[26]  M. Ingelman-Sundberg,et al.  In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. , 1997, Biochemical and biophysical research communications.

[27]  C. Kiyohara,et al.  The Relationship between Aryl Hydrocarbon Hydroxylase and Polymorphisms of the CYP1A1 Gene , 1996, Japanese journal of cancer research : Gann.

[28]  O. Hankinson,et al.  An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. , 2000, Pharmacogenetics.

[29]  S. Anttila,et al.  Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. , 1995, Carcinogenesis.